Amarin (AMRN) to Release Earnings on Wednesday

Amarin (NASDAQ:AMRN - Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect Amarin to post earnings of ($0.04) per share for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.

Amarin (NASDAQ:AMRN - Get Free Report) last posted its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.04. Amarin had a negative net margin of 19.26% and a negative return on equity of 10.47%. The business had revenue of $74.71 million for the quarter, compared to analyst estimates of $72.46 million. On average, analysts expect Amarin to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amarin Stock Performance

Amarin stock remained flat at $0.88 during mid-day trading on Wednesday. 657,243 shares of the company's stock were exchanged, compared to its average volume of 1,986,488. Amarin has a 12-month low of $0.65 and a 12-month high of $1.49. The stock's 50 day simple moving average is $0.99 and its 200 day simple moving average is $0.93. The stock has a market cap of $360.81 million, a price-to-earnings ratio of -6.28 and a beta of 1.98.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Amarin in a report on Friday, January 12th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $1.08.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.